Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

Kraus, Michael R.; Schäfer, Arne; Schöttker, Katrin; Keicher, Christian; Weißbrich, Benedikt; Hofbauer, I; Scheurlen, Michael

doi:10.1136/gut.2007.131607

Cited by 117 publications

(89 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although prophylaxis of IFN-induced depression with antidepressants remains controversial, 22 pharmacological treatment of depression after its onset has proven effective and beneficial. 3,23 concluSIonS…”

Section: Resultsmentioning

confidence: 99%

Interferon-induced depression in patients with hepatitis C: an epidemiologic study

Medeiros

Kayo

Medeiros

et al. 2014

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Conflict of interest: noneObjective: To assess the incidence rate and severity of depressive symptoms in different time points (12, 24 and 48 weeks) in Brazilian patients with HCV treated with PEG IFN plus ribavirin. Methods:We conducted an observational prospective study using the Beck Depression Inventory (BDI) and the Center for Epidemiologic Studies Depression Scale (CES-D). Results: Fifty patients were included. The assessments with either scale showed the highest score of depressive symptoms in the 24 th week of treatment; the mean BDI score before treatment was 6.5 ± 5.3 and the mean CES-D was 10.9 ± 7.8. After 24 weeks, the mean BDI was 16.1 ± 10.2 and mean CES-D was 18.6 ± 13.0; 46% were diagnosed with depression according to combined BDI and CES-D scores. The somatic/psychomotor subscales were highly correlated with overall scale scores . Subjects with history of substance and alcohol abuse had higher risk for IFN--induced depression. Conclusion: Treatment with PEG IFN was associated with a high incidence rate of depressive symptoms in this sample of Brazilian patients, as measured by CES-D and BDI. Alcohol and substance abuse increase the risk of PEG IFN-induced depression.

show abstract

Section: Resultsmentioning

confidence: 99%

Interferon-induced depression in patients with hepatitis C: an epidemiologic study

Medeiros

Kayo

Medeiros

et al. 2014

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…35 Kraus et al demonstrated in a randomised, placebo-controlled trial, that 20 mg citalopram daily was significantly superior to placebo in reducing interferon-related depressive symptoms after 2 and 4 weeks. 92 A significant improvement in major depression was found in interferon-treated HCV patients managed concomitantly with 20 mg paroxetine, 93 allowing 79% of the subjects who had developed depression to complete interferon treatment. Certainly, SSRI use in chronic HCV patients does not appear to have any additional adverse effects in most case series and trials.…”

mentioning

confidence: 99%

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Mullish

Kabir

Thursz

et al. 2014

Aliment Pharmacol Ther

107

View full text Add to dashboard Cite

SummaryBackgroundThe scale of depression in patients with chronic liver disease (CLD) and those who have received orthotopic liver transplantation (OLT) is poorly characterised. Clinicians are uncertain of how best to manage depression within these patients.AimsTo review the literature evaluating both the prevalence and impact of depression in patients with CLD and post‐OLT, and to assess the safety and efficacy of antidepressant use within this context.MethodsA PubMed search using the phrases ‘chronic liver disease’, ‘cirrhosis’, ‘liver transplantation’, ‘depression’, ‘antidepressant’ and the names of specific causes of liver disease and individual antidepressants.ResultsOver 30% of cirrhotic patients have depressive features, and they experience worse clinical outcomes than nondepressed cirrhotic patients. CLD patients with chronic hepatitis C are particularly prone to depression, partly related to the use of interferon therapy. OLT patients with depression have higher mortality rates than nondepressed patients; appropriate antidepressant use reverses this effect. Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) are effective and generally safe in both CLD and OLT patients.ConclusionsDepression is much more prevalent in CLD or OLT patients than is generally recognised, and it adversely affects clinical outcomes. The reasons for this relationship are complex and multifactorial. Antidepressants are effective in both CLD and post‐OLT, although lower doses or a reduced dosing frequency may be required to minimise side effects, e.g. exacerbation of hepatic encephalopathy. Further research is needed to establish optimal management of depression in these patients, including the potential role of nonpharmacological treatments.

show abstract

“…С другой стороны, в современной литературе широко обсужда-ется феномен «цитокин-индуцированной депрессии» (Kalyoncu O.A., 2005;Pace T., 2007;Beckwith A.R., 2008;Kraus M.R., 2008;Schaefer M., 2008). Рост уровня биомаркеров воспаления (в частности, ИЛ-6) кор-релирует с депрессивными симптомами, а применение цитокиновой терапии сопровождается симптомами усталости, анергии (Miller A.H., Raison C.L., 2008).…”

Section: иммунологические подходы к оптимизации терапии депрессивных unclassified

“…2.4, в литературе широко обсуждается феномен «цитокин-индуцированной депрессии» (Kalyoncu O.A. et al, 2005;Pace T. et al, 2007;Beckwith A.R., 2008;Kraus M.R. et al, 2008;Schaefer M. et al, 2008).…”

Section: возможность применения сверхмалых доз антител в комплексной unclassified

Technology of Immunocorrection at Mental Disorders

Vetlugina¹,

Nevidimova²,

Lobacheva³

et al. 2010

View full text Add to dashboard Cite

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

Abstract: The findings demonstrate clearly that citalopram treatment is highly effective in HCV patients on interferon therapy, when initiated after the onset of clinically relevant depressive symptoms. This suggests that a general SSRI prophylaxis is not necessary in these patients.

Cited by 117 publications

References 31 publications

Interferon-induced depression in patients with hepatitis C: an epidemiologic study

Interferon-induced depression in patients with hepatitis C: an epidemiologic study

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Technology of Immunocorrection at Mental Disorders

Contact Info

Product

Resources

About